PMID- 28950433
OWN - NLM
STAT- MEDLINE
DCOM- 20180823
LR  - 20180823
IS  - 2047-2927 (Electronic)
IS  - 2047-2919 (Linking)
VI  - 6
IP  - 1
DP  - 2018 Jan
TI  - Effects of testosterone supplementation therapy on lipid metabolism in 
      hypogonadal men with T2DM: a meta-analysis of randomized controlled trials.
PG  - 37-46
LID - 10.1111/andr.12425 [doi]
AB  - Testosterone supplementation may be effective for the treatment of hypogonadism 
      in men with type 2 diabetes mellitus (T2DM), but the evidence from randomized 
      controlled trials (RCTs) is inconclusive. We aimed to systematically summarize 
      results from intervention studies and assess the effects of testosterone 
      supplementation therapy (TST) on lipid metabolism in RCTs of hypogonadal men with 
      T2DM by meta-analysis. PubMed, Embase, and Cochrane Library databases were 
      searched for studies reporting the effect of TST on lipid metabolism in 
      hypogonadal men with T2DM until December 31, 2016. Seven RCTs from 252 trials, 
      enrolling a total of 612 patients in the experimental and control groups with a 
      mean age of 58.5 years, were included in this study. The pooled results of the 
      meta-analysis demonstrated that TST significantly decreased TC and TG levels in 
      hypogonadal men with T2DM compared with the control group, with mean differences 
      (MDs) of -6.44 (95% CI: -11.82 to -1.06; I(2 ) = 28%; p = 0.02) and -27.94 (95% 
      CI: -52.33 to -3.54; I(2 ) = 76%; p = 0.02). Subgroup analyses revealed that the 
      heterogeneity (I(2 ) = 76%) of TG originated from different economic regions, in 
      which economic development, genetic and environmental factors, and dietary habits 
      affect lipid metabolism of human, with a decrease (I(2 ) = 45%) in developed 
      countries. Additionally, subgroup analyses showed that TST increased HDL-C level 
      in developing countries compared with the control group (MD = 2.79; 95% CI: 0.73 
      to 4.86; I(2 ) = 0%; p = 0.008), but there was no improvement in developed 
      countries (MD = 1.02; 95% CI: -4.55 to 6.60; I(2 ) = 91%; p = 0.72). However, 
      LDL-C levels were not improved consistently. Because the relationship between 
      lipid metabolism and atherosclerosis is unequivocal, TST, which ameliorates lipid 
      metabolism, may decrease the morbidity and mortality of cardiovascular disease in 
      hypogonadal men with T2DM by preventing atherogenesis.
CI  - (c) 2017 American Society of Andrology and European Academy of Andrology.
FAU - Zhang, K-S
AU  - Zhang KS
AD  - Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical 
      College, Beijing, China.
AD  - National Health and Family Planning Key Laboratory of Male Reproductive Health, 
      Department of Male Clinical Research, National Research Institute for Family 
      Planning & WHO Collaborating Center for Research in Human Reproduction, Beijing, 
      China.
FAU - Zhao, M-J
AU  - Zhao MJ
AD  - Department of Reproduction and Genetics, Maternity and Child Health Care 
      Hospital, Tangshan, China.
FAU - An, Q
AU  - An Q
AD  - Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical 
      College, Beijing, China.
AD  - National Health and Family Planning Key Laboratory of Male Reproductive Health, 
      Department of Male Clinical Research, National Research Institute for Family 
      Planning & WHO Collaborating Center for Research in Human Reproduction, Beijing, 
      China.
FAU - Jia, Y-F
AU  - Jia YF
AD  - Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical 
      College, Beijing, China.
AD  - National Health and Family Planning Key Laboratory of Male Reproductive Health, 
      Department of Male Clinical Research, National Research Institute for Family 
      Planning & WHO Collaborating Center for Research in Human Reproduction, Beijing, 
      China.
FAU - Fu, L-L
AU  - Fu LL
AD  - Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical 
      College, Beijing, China.
AD  - National Health and Family Planning Key Laboratory of Male Reproductive Health, 
      Department of Male Clinical Research, National Research Institute for Family 
      Planning & WHO Collaborating Center for Research in Human Reproduction, Beijing, 
      China.
FAU - Xu, J-F
AU  - Xu JF
AD  - National Health and Family Planning Key Laboratory of Male Reproductive Health, 
      Department of Male Clinical Research, National Research Institute for Family 
      Planning & WHO Collaborating Center for Research in Human Reproduction, Beijing, 
      China.
FAU - Gu, Y-Q
AU  - Gu YQ
AUID- ORCID: 0000-0001-9848-811X
AD  - Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical 
      College, Beijing, China.
AD  - National Health and Family Planning Key Laboratory of Male Reproductive Health, 
      Department of Male Clinical Research, National Research Institute for Family 
      Planning & WHO Collaborating Center for Research in Human Reproduction, Beijing, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20170926
PL  - England
TA  - Andrology
JT  - Andrology
JID - 101585129
RN  - 0 (Androgens)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Aged
MH  - Androgens/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Eunuchism/*drug therapy/etiology
MH  - Humans
MH  - Lipid Metabolism/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Testosterone/*therapeutic use
OTO - NOTNLM
OT  - diabetes
OT  - hypogonadism
OT  - lipids
OT  - testosterone
OT  - treatment
EDAT- 2017/09/28 06:00
MHDA- 2018/08/24 06:00
CRDT- 2017/09/27 06:00
PHST- 2017/03/07 00:00 [received]
PHST- 2017/08/04 00:00 [revised]
PHST- 2017/08/09 00:00 [accepted]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2018/08/24 06:00 [medline]
PHST- 2017/09/27 06:00 [entrez]
AID - 10.1111/andr.12425 [doi]
PST - ppublish
SO  - Andrology. 2018 Jan;6(1):37-46. doi: 10.1111/andr.12425. Epub 2017 Sep 26.